Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.49 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18696400 | 1.00 | CPN1 (0.49) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL9289911 | 0.90 | CPN1 (0.37) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL19816009 | 0.82 | CPN1 (0.59) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL6915115 | 0.81 | CPN1 (0.46) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| Hydrochloric Acid SCHEMBL11447118 | 0.81 | CPN1 (0.57) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL26502995 | 0.81 | CPN1 (0.41) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL18739893 | 0.79 | CPN1 (0.47) | CPN1CPB2SLC6A1SLC6A11TSHR | |
| SCHEMBL11932955 | 0.79 | — | — | |
| SCHEMBL9289846 | 0.77 | CPN1 (0.44) | CPN1CPB2TSHRLMNA | |
| SCHEMBL20290147 | 0.77 | EPHX1 (0.41) | LMNASMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3150617-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-2217610-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9266919-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-8822424-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8658606-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8653042-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130217642-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217642-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CPN1 4270/4885CPB2 4693/4885SLC6A1 4038/4885 |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | CPN1 3851/4885CPB2 4271/4885SLC6A1 4050/4885 |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CPN1 4270/4885CPB2 4693/4885SLC6A1 4038/4885 |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CPN1 4270/4885CPB2 4693/4885SLC6A1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.